(E)-4-chloro-2-styrylphenol | 89122-71-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-4-chloro-2-styrylphenol
• 英文别名: 4-Chloro-2-styrylphenol；4-chloro-2-[(E)-2-phenylethenyl]phenol
• CAS: 89122-71-4
• 化学式: C₁₄H₁₁ClO
• 分子量: 230.694
• InChiKey: DFHXKRFNZBTAJG-VOTSOKGWSA-N

物化性质

• 沸点：
  374.3±21.0 °C(Predicted)
• 密度：
  1.260±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-4-chloro-2-styrylphenol 在 氢氧化钾 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 11.0h， 生成 1-{4-[4-Chloro-2-((E)-styryl)-phenoxy]-butyl}-piperidin-3-ol
  参考文献：
  名称：

  取代的（ω-氨基烷氧基）二苯乙烯衍生物作为一类新的抗惊厥药。

  摘要：

  已合成了一系列取代的（ω-氨基烷氧基）二苯乙烯衍生物，并筛选了其抗惊厥活性。已经系统地检查了这些分子的结构修饰对活性的影响。2- [4-（4-甲基-1哌嗪基）丁氧基] sti烯（20）和某些2- [4-（3-烷氧基-1-哌啶基）丁氧基] sti烯衍生物（21，37， 38和40），通过最大电击惊厥（MES）和戊四氮诱发的小鼠惊厥试验确定。在大鼠的进一步药理试验中，化合物21的抗MES活性比二苯乙内酰脲和卡马西平更强，其治疗指数优于两种抗癫痫药。

  DOI：

  10.1021/jm00371a015
• 作为产物：
  描述：

  4-氯-2-(1-羟基-2-苯基-乙基)-苯酚 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 (E)-4-chloro-2-styrylphenol
  参考文献：
  名称：

  取代的（ω-氨基烷氧基）二苯乙烯衍生物作为一类新的抗惊厥药。

  摘要：

  已合成了一系列取代的（ω-氨基烷氧基）二苯乙烯衍生物，并筛选了其抗惊厥活性。已经系统地检查了这些分子的结构修饰对活性的影响。2- [4-（4-甲基-1哌嗪基）丁氧基] sti烯（20）和某些2- [4-（3-烷氧基-1-哌啶基）丁氧基] sti烯衍生物（21，37， 38和40），通过最大电击惊厥（MES）和戊四氮诱发的小鼠惊厥试验确定。在大鼠的进一步药理试验中，化合物21的抗MES活性比二苯乙内酰脲和卡马西平更强，其治疗指数优于两种抗癫痫药。

  DOI：

  10.1021/jm00371a015

文献信息

• Tetrahydropyrrolization of Resveratrol and Other Stilbenes Improves Inhibitory Effects on DNA Oxidation
  作者：Liang-Liang Bao、Zai-Qun Liu

  DOI：10.1002/cmdc.201600205

  日期：2016.8.5

  stilbenes, because the tetrahydropyrrole motif can provide hydrogen atoms to be abstracted by radicals. Therefore, the tetrahydropyrrolization offered an advantage for enhancing the antioxidant effects of stilbenes. Notably, (CH3)3SiCH2N(CH3)CH2OCH3 (in the presence of CF3COOH) and (CH3)3NO (in the presence of LiN(iPr)2) can be used to generate azomethine ylide for the tetrahydropyrrolization of stilbenes

  如果白藜芦醇中的C = C键通过与偶氮甲碱内酯（CH 2）反应转化为四氢吡咯，发现白藜芦醇对2,2'-偶氮二（2-ami胺丙烷盐酸盐）（AAPH）引起的DNA氧化的抑制作用增强。= N +（CH 3）CH 2 -）。这鼓励我们探讨是否也可以通过相同的方法提高其他对苯乙烯的抑制活性。我们发现四氢吡咯衍生物对AAPH诱导的DNA氧化的抑制作用高于相应的对苯二酚，因为四氢吡咯基序可以提供氢原子以被自由基提取。因此，四氢吡咯化提供了增强对苯乙烯的抗氧化作用的优点。值得注意的是，（CH 3）3 SiCH 2 N（CH 3）CH 2 OCH 3（在CF 3 COOH存在下）和（CH 3）3 NO（在LiN（iPr）2）可用于生成甲亚胺叶立德，分别用于含吸电子和供电子基团的对苯二甲酸酯的四氢吡咯化。
• Asymmetric syntheses of spiro[benzofuro-cyclopenta[1,2-<i>b</i>]indole–indoline] scaffolds <i>via</i> consecutive cyclization
  作者：Heng Zhang、Xu-Kai Guan、Dong-Yang Sun、Guo-Feng Liu、Ji-Gang Gao、Guang-Liang Zhang、Suo-Qin Zhang

  DOI：10.1039/d0cc08083g

  日期：——

  An efficient method to construct enantioenriched spiro[benzofuro-cyclopenta[1,2-b]indole–indoline] scaffolds via consecutive cyclization is described here. The new scaffolds possess five successive chiral stereogenic centers and two spiroheterocycles. A range of highly enantioenriched scaffolds has been obtained with up to 93% yield, 99% ee and >19 : 1 d.r. catalyzed by Brønsted acid catalysts.

  本文描述了一种通过连续环化来构建对映体富集的螺[苯并呋喃-环戊五[1,2 - b ]吲哚-吲哚啉]支架的有效方法。新的支架具有五个连续的手性立体发生中心和两个螺杂环。已经获得了一系列高度对映体富集的支架，其通过布朗斯台德酸催化剂催化的产率高达93％，ee为99％，dr> 19：1 dr。
• Inhibitors against the activation of ap-1 and nfat
  申请人：Muto Susumu

  公开号：US20060100257A1

  公开（公告）日：2006-05-11

  A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物，抑制AP-1的激活，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种，其中X代表连接基，其主链中的原子数为2至5（该连接基可以被取代），A代表氢原子或乙酰基，E代表芳基或取代的杂芳基，环Z代表芳烃，除了由式—O-A所表示的基团外，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义，或者是一个杂芳烃，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义。
• Antiallergic
  申请人：Muto Susumu

  公开号：US20060122243A1

  公开（公告）日：2006-06-08

  A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中X代表主链中原子数为2到5的连接基（该连接基可以被取代），A代表氢原子或乙酰基，E代表可以被取代的芳基或杂环芳基，环Z代表可以具有一个或多个取代基的芳烃，除了由公式-O-A所表示的基团外，该芳烃还可以具有公式—X-E所表示的基团，其中每个X和E具有上述定义的相同含义，或者该环可以具有一个或多个取代基，除了由公式—O-A所表示的基团外，该环还可以具有公式—X-E所表示的基团，其中A具有上述定义的相同含义，X和E分别具有上述定义的相同含义。
• ANTIALLERGIC AGENTS
  申请人：Muto Susumu

  公开号：US20080090779A1

  公开（公告）日：2008-04-17

  A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其包括以下通式（I）所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中X表示连接基，其主链中原子数为2至5（该连接基可以被取代），A表示氢原子或乙酰基，E表示芳基或取代的杂芳基，环Z表示苯环，除了由公式-O-A表示的基团，该苯环还可以具有一个或多个取代基团，其中A的含义与上述定义相同，而由公式-X-E表示的基团中，每个X和E的含义也与上述定义相同，或者是一个杂环，除了由公式-O-A表示的基团，该杂环还可以具有一个或多个取代基团，其中A的含义与上述定义相同，而由公式-X-E表示的基团中，每个X和E的含义也与上述定义相同。